Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Champions Oncology Inc.

    NASDAQ: CSBR · Real-Time Price · USD
    6.47
    0.09 (1.41%)
    At close: Jun 05, 2025, 3:59 PM
    6.43
    -0.62%
    After-hours: Jun 05, 2025, 03:59 PM EDT

    Champions Oncology Statistics

    Share Statistics

    Champions Oncology has 13.83M shares outstanding. The number of shares has increased by 1.71% in one year.

    Shares Outstanding

    n/a
    		 13.83M

    Shares Change (YoY)

    n/a
    		 1.71%

    Shares Change (QoQ)

    n/a
    		 0.06%

    Owned by Institutions (%)

    n/a
    		 42.07%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 8

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    The latest short interest is 106.43K, so 0.77% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 106.43K

    Short % of Shares Out

    n/a
    		 0.77%

    Short % of Float

    n/a
    		 1.86%

    Short Ratio (days to cover)

    n/a
    		 2.38

    Valuation Ratios

    The PE ratio is -9.03 and the forward PE ratio is 29.14. Champions Oncology's PEG ratio is -0.23.

    PE Ratio

    n/a
    		 -9.03

    Forward PE

    n/a
    		 29.14

    PS Ratio

    n/a
    		 1.31

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 -34.53

    P/FCF Ratio

    n/a
    		 -9.42

    PEG Ratio

    n/a
    		 -0.23
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Champions Oncology.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.63, with a Debt / Equity ratio of -3.9.

    Current Ratio

    n/a
    		 0.63

    Quick Ratio

    n/a
    		 0.63

    Debt / Equity

    n/a
    		 -3.9

    Debt / EBITDA

    n/a
    		 -1.47

    Debt / FCF

    n/a
    		 -1.07

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $238,833.33

    Profits Per Employee

    n/a
    		 $-34,647.62

    Employee Count

    n/a
    		 210

    Asset Turnover

    n/a
    		 1.92

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -32K

    Effective Tax Rate

    n/a
    		 0.44%

    Stock Price Statistics

    The stock price has increased by 39.14% in the last 52 weeks. The beta is 0.37, so Champions Oncology's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.37

    52-Week Price Change

    n/a
    		 39.14%

    50-Day Moving Average

    n/a
    		 7.1

    200-Day Moving Average

    n/a
    		 6.92

    Relative Strength Index (RSI)

    n/a
    		 51.02

    Average Volume (20 Days)

    n/a
    		 37,788

    Income Statement

    In the last 12 months, Champions Oncology had revenue of 50.16M and earned -7.28M in profits. Earnings per share was -0.54.

    Revenue

    n/a
    		 50.16M

    Gross Profit

    n/a
    		 20.75M

    Operating Income

    n/a
    		 -7.36M

    Net Income

    n/a
    		 -7.28M

    EBITDA

    n/a
    		 -5.05M

    EBIT

    n/a
    		 -6.92M

    Earnings Per Share (EPS)

    n/a
    		 -0.54
    Full Income Statement

    Balance Sheet

    The company has 2.62M in cash and 7.43M in debt, giving a net cash position of -4.81M.

    Cash & Cash Equivalents

    n/a
    		 2.62M

    Total Debt

    n/a
    		 7.43M

    Net Cash

    n/a
    		 -4.81M

    Retained Earnings

    n/a
    		 -84.59M

    Total Assets

    n/a
    		 30.63M

    Working Capital

    n/a
    		 -173K
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -6.14M and capital expenditures -836K, giving a free cash flow of -6.97M.

    Operating Cash Flow

    n/a
    		 -6.14M

    Capital Expenditures

    n/a
    		 -836K

    Free Cash Flow

    n/a
    		 -6.97M

    FCF Per Share

    n/a
    		 -0.51
    Full Cash Flow Statement

    Margins

    Gross margin is 41.38%, with operating and profit margins of -14.67% and -14.51%.

    Gross Margin

    n/a
    		 41.38%

    Operating Margin

    n/a
    		 -14.67%

    Pretax Margin

    n/a
    		 -14.57%

    Profit Margin

    n/a
    		 -14.51%

    EBITDA Margin

    n/a
    		 -10.08%

    EBIT Margin

    n/a
    		 -14.67%

    FCF Margin

    n/a
    		 -13.9%

    Dividends & Yields

    CSBR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CSBR is $12, which is 85.5% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $12

    Price Target Difference

    n/a
    		 85.5%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Aug 12, 2015. It was a backward split with a ratio of 1:12.

    Last Split Date

    n/a
    		 Aug 12, 2015

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:12

    Scores

    Altman Z-Score

    n/a
    		 4.6

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist